Symbols

ABVX

Abivax·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 0

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ABVX

Abivax Sa

A biotechnology company focused on harnessing the body's natural regulatory mechanisms to modulate the clinical stages of chronic inflammatory diseases

Industry

Biological Technology

Established Date

12/04/2013

Listing Date

10/20/2023

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.abivax.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

7-11 boulevard Haussmann, 75009 Paris, France

Business

Introduction

Abivax Sa was incorporated on December 4, 2013 under the laws of France. The company is a clinical-stage biotechnology company focused on developing therapies that leverage the body's natural regulatory mechanisms to stabilize immune responses in chronic inflammatory diseases. Its lead drug candidate, obefazimod, is in Phase 3 development for the treatment of ulcerative colitis and is being developed for Crohn's disease.

Company Financials

EPS

Revenue & Expenses

ABVX has released its 2025 Q4 earnings report, with revenue of 516.38K, reflecting a YoY change of -88.43%, and net profit of -96.19M, showing a YoY change of -135.99%. The Sankey diagram below clearly presents ABVX's revenue sources and cost distribution.